Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation-Reference-Cited by-同舟云学术

Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Published:2014-11-25 Issue:7 Volume:121 Page:1048-1055
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Baron Frédéric¹,Labopin Myriam²³⁴⁵,Peniket Andy⁶,Jindra Pavel⁷,Afanasyev Boris⁸,Sanz Miguel A.⁹,Deconinck Eric¹⁰,Nagler Arnon³¹¹,Mohty Mohamad²³⁴⁵

Affiliation:

1. Department of Hematology; University of Liege; Liege Belgium

2. Clinical Hematology and Cellular Therapy Department; Saint Antoine Hospital; Paris France

3. Acute Leukemia Working Party Office, European Group for Blood and Marrow Transplantation, Saint Antoine Hospital; Paris France

4. Pierre and Marie Curie University; Paris France

5. Joint Research Unit 938, National Institute of Health and Medical Research; Paris France

6. Bone Marrow Transplant Unit; Haematology Department; Radcliffe Hospital; Oxford United Kingdom

7. Charles University Medical School and Teaching Hospital; Pilsen Czech Republic

8. R. Gorbacheva Memorial Institute of Oncology; Hematology; and Transplantation; St Petersburg State Medical I. P. Pavlov University; St Petersburg Russia

9. Hematology Department; La Fe University and Polytechnic Hospital; Valencia Spain

10. Department of Hematology; University Hospital; Besancon France

11. Hematology Division; Chaim Sheba Medical Center, Tel-Aviv University; Tel-Hashomer Israel

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29163/fullpdf

Reference27 articles.

1. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia;Estey;Leukemia,2013

2. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival;Burnett;Blood,2013